GPs in England will be incentivized to refer patients to weight loss programs and prescribe drugs such as tirzepatide (Mounjaro) under the 2026-27 contract. The Government will provide £25 million to add two new indicators to the Quality and Outcomes Framework. These indicators include better recording of body mass index (BMI) and offering weight management support to obese adults. The aim is to more consistently identify and support obese patients across England. Experts warn that this incentive for GPs will not solve problems with the introduction of weight loss drugs. Health Secretary Wes Streeting said the indicators would help bring about changes in access to these drugs.